Expression of mGlu Receptor Genes in the Hippocampus After Intoxication with Trimethyltin
- 15 Downloads
A variety of localization and signaling properties of eight subtypes of metabotropic glutamate receptors (mGluRs) in the brain provide glutamate an important regulatory role in many processes, including neurodegeneration and repair of neuronal damage. To identify specific subtypes of mGluRs, which are involved in neurodegeneration process, we assessed expression levels of their genes under pathophysiological conditions. Using quantitative real-time RT-PCR analysis, we studied transcription levels of mGlu2-5 and mGlu7 genes in the hippocampus after its damage by neurotoxicant trimethyltin chloride (TMT) in Wistar rats. This organotin compound is known to cause neurodegeneration in the brain, especially in the hippocampus. Morphological studies confirmed neuronal damage in CA3-CA4 subfields of the hippocampus 6 weeks after the treatment with TMT. Step-through passive avoidance test revealed memory deterioration in rat-treated TMT. Interestingly, 3 and 6 weeks after the treatment with TMT, expression levels of the mGlu2 and mGlu7 genes were not changed in comparison to the control values while expression level of mGlu4 genes was upregulated throughout the whole studied period of TMT action. The dynamics of mGlu3 gene expression revealed the existence of neuroinflammation 3 weeks after the treatment with TMT, which was further confirmed by the upregulation of cyclooxygenase-2 gene expression. The expression level of mGlu5 receptors was downregulated 6 weeks after the treatment with TMT. Our results revealed a significant role of mGlu4, mGlu5, and mGlu3 receptors in the neurodegenerative/reparative processes in the hippocampus after the treatment with TMT. Ligands of these receptor subtypes can be, therefore, considered potential therapeutic targets for prevention or reduction of neurodegeneration.
KeywordsTrimethyltin chloride Hippocampus Metabotropic glutamate receptors Gene expression
This work was supported by Russian Foundation for Basic Research (Grant No. 16-34-01167).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- Amalric M, Lopez S, Goudet C, Fisone G, Battaglia G, Nicoletti F, Pin JP, Acher FC (2013) Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology 66:53–64. https://doi.org/10.1016/j.neuropharm.2012.05.026 CrossRefPubMedGoogle Scholar
- Arkhipov V, Kapralova M, Pershina E, Gordon R (2014) Delayed treatments with pharmacological modulators of pre- and postsynaptic mGlu receptors rescue the hippocampus from kainate-induced neurodegeneration. Neurosci Lett 570:5–9. https://doi.org/10.1016/j.neulet.2014.04.012 CrossRefPubMedGoogle Scholar
- Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013–1033. https://doi.org/10.1097/00004647-200109000-00001 CrossRefPubMedGoogle Scholar
- Bruno V, Caraci F, Copani A, Matrisciano F, Nicoletti F, Battaglia G (2017) The impact of metabotropic glutamate receptors into active neurodegenerative processes: a “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology 115:180–192. https://doi.org/10.1016/j.neuropharm.2016.04.044 CrossRefPubMedGoogle Scholar
- Cannella M, Motolese M, Bucci D, Molinaro G, Gradini R, Bruno V, Nicoletti F, Battaglia G (2015) Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology 95:50–58. https://doi.org/10.1016/j.neuropharm.2015.02.024 CrossRefPubMedGoogle Scholar
- Lattanzi W, Corvino V, Di Maria V, Michetti F, Geloso MC (2013) Gene expression profiling as a tool to investigate the molecular machinery activated during hippocampal neurodegeneration induced by trimethyltin (TMT) administration. Int J Mol Sci 14:16817–16835. https://doi.org/10.3390/ijms140816817 CrossRefPubMedPubMedCentralGoogle Scholar
- Lee S, Yang M, Kim J, Kang S, Kim J, Kim JC, Jung C, Shin T, Kim SH, Moon C (2016) Trimethyltin-induced hippocampal neurodegeneration: a mechanism-based review. Brain Res Bull 125:187–199. https://doi.org/10.1016/j.brainresbull.2016.07.010 CrossRefPubMedGoogle Scholar
- Little AR, Miller DB, Li S, Kashon ML, O'Callaghan JP (2012) Trimethyltin-induced neurotoxicity: gene expression pathway analysis, q-RT-PCR and immunoblotting reveal early effects associated with hippocampal damage and gliosis. Neurotoxicol Teratol 34:72–82. https://doi.org/10.1016/j.ntt.2011.09.012 CrossRefPubMedGoogle Scholar
- Moyanova SG, Mastroiacovo F, Kortenska LV, Mitreva RG, Fardone E, Santolini I, Sobrado M, Battaglia G, Bruno V, Nicoletti F, Ngomba RT (2011) Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage. J Cereb Blood Flow Metab 31:1107–1118. https://doi.org/10.1038/jcbfm.2010.201 CrossRefPubMedGoogle Scholar
- Pershina EV, Kapralova MV, Arkhipov VI (2017) Effect of pharmacological modulation of activity of metabotropic glutamate receptors on their gene expression after excitotoxic damage in hippocampal neurons. Bull Exp Biol Med 162:784–787. https://doi.org/10.1007/s10517-017-3713-2 CrossRefPubMedGoogle Scholar
- Wong RKS, Bianchi R, Chuang S-C, Merlin LR (2005) Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and implications for antiepileptic drug design. Epilepsy Curr 5:63–68. https://doi.org/10.1111/j.1535-7597.2005.05207 CrossRefPubMedPubMedCentralGoogle Scholar